- Home
- LSAK vs AGEN Comparison
LSAK vs AGEN Comparison
Compare LSAK & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSAK
- AGEN
- Stock Information
- Founded
- LSAK 1997
- AGEN 1994
- Country
- LSAK South Africa
- AGEN United States
- Employees
- LSAK N/A
- AGEN N/A
- Industry
- LSAK Investment Bankers/Brokers/Service
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LSAK Finance
- AGEN Health Care
- Exchange
- LSAK Nasdaq
- AGEN Nasdaq
- Market Cap
- LSAK N/A
- AGEN 97.7M
- IPO Year
- LSAK N/A
- AGEN 2000
- Fundamental
- Price
- LSAK $5.10
- AGEN $4.49
- Analyst Decision
- LSAK
- AGEN Buy
- Analyst Count
- LSAK 0
- AGEN 3
- Target Price
- LSAK N/A
- AGEN $10.00
- AVG Volume (30 Days)
- LSAK 18.4K
- AGEN 339.2K
- Earning Date
- LSAK 11-06-2024
- AGEN 11-05-2024
- Dividend Yield
- LSAK N/A
- AGEN N/A
- EPS Growth
- LSAK N/A
- AGEN N/A
- EPS
- LSAK N/A
- AGEN N/A
- Revenue
- LSAK $564,222,000.00
- AGEN $159,630,000.00
- Revenue This Year
- LSAK $6.62
- AGEN N/A
- Revenue Next Year
- LSAK $7.87
- AGEN $0.04
- P/E Ratio
- LSAK N/A
- AGEN N/A
- Revenue Growth
- LSAK 6.87
- AGEN 60.67
- 52 Week Low
- LSAK $3.00
- AGEN $4.18
- 52 Week High
- LSAK $5.33
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- LSAK 58.96
- AGEN 40.14
- Support Level
- LSAK $4.99
- AGEN $4.50
- Resistance Level
- LSAK $5.08
- AGEN $4.78
- Average True Range (ATR)
- LSAK 0.11
- AGEN 0.28
- MACD
- LSAK 0.01
- AGEN 0.02
- Stochastic Oscillator
- LSAK 100.00
- AGEN 42.47
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).